Page last updated: 2024-11-13

ornithine phenylacetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID44247677
CHEMBL ID4297204
SCHEMBL ID1702338
MeSH IDM0573776

Synonyms (23)

Synonym
952154-79-9
D09942
ornithine phenylacetate (usan)
op
ornithine phenylacetate
l-op
9d6yz105sn ,
ocr-002
unii-9d6yz105sn
ornithine phenylacetate [usan]
l-ornithine phenylacetate
op [ammonia detoxifying agent]
l-ornithine phenyl acetate
LRSYFEZBIMVWRY-VWMHFEHESA-N
SCHEMBL1702338
ornithine phenylacetate [who-dd]
l-ornithine, benzeneacetate (1:1)
(2s)-2,5-diaminopentanoic acid phenylacetate (1:1)
DTXSID90241788
Q27272385
AT24078
mnk-6105
CHEMBL4297204

Research Excerpts

Overview

Ornithine phenylacetate (OP) is a new drug that has been proposed for the treatment of hepatic encephalopathy (HE) because it decreases plasma ammonia.

ExcerptReferenceRelevance
"Ornithine phenylacetate (OP) is a novel drug that is targeted at reducing ammonia concentration in patients with liver disease and therefore a potential treatment for HE."( Ornithine phenylacetate revisited.
Jalan, R; Jover-Cobos, M; Noiret, L; Sharifi, Y, 2013
)
2.55
"Ornithine phenylacetate (OP) is a new drug that has been proposed for the treatment of hepatic encephalopathy (HE) because it decreases plasma ammonia. "( Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis.
Arranz, JA; Córdoba, J; Oria, M; Raguer, N; Riudor, E; Romero-Giménez, J, 2012
)
3.26

Toxicity

ExcerptReferenceRelevance
" OP is safe in healthy subjects and in stable patients with cirrhosis, but there are no data in decompensated cirrhosis."( Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Arranz, JA; Blanco, A; Córdoba, J; Fuentes, I; Riudor, E; Simón-Talero, M; Soriano, G; Suñé, P; Torrens, M; Ventura-Cots, M,
)
0.53
"No severe adverse events were observed."( Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Arranz, JA; Blanco, A; Córdoba, J; Fuentes, I; Riudor, E; Simón-Talero, M; Soriano, G; Suñé, P; Torrens, M; Ventura-Cots, M,
)
0.53
"OP is a safe and well-tolerated drug in decompensated cirrhotics that may decrease plasma ammonia by inducing its appearance as phenylacetylglutamine in urine."( Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Arranz, JA; Blanco, A; Córdoba, J; Fuentes, I; Riudor, E; Simón-Talero, M; Soriano, G; Suñé, P; Torrens, M; Ventura-Cots, M,
)
0.53
" Of the reported serious adverse events (AEs), which included 11 deaths, none was attributable to study medication."( Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.
Bukofzer, S; Clasen, K; Durkalski, V; Fontana, RJ; Ganger, D; Gottfried, M; Hameed, B; Hanje, AJ; Koch, D; Lee, WM; Little, L; Ravis, WR; Sherker, A; Stravitz, RT; Subramanian, RM, 2018
)
0.74
" The percentages of patients with any specific adverse event did not differ significantly between groups."( Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Bajaj, JS; Bhamidimarri, KR; Bukofzer, S; Potthoff, A; Pyrsopoulos, N; Rahimi, RS; Safadi, R; Thabut, D, 2021
)
0.93
" However, OP appears to be safe and should undergo further testing for treatment of hyperammonemia in hospitalized patients receiving treatment for the underlying precipitant of acute or overt HE."( Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Bajaj, JS; Bhamidimarri, KR; Bukofzer, S; Potthoff, A; Pyrsopoulos, N; Rahimi, RS; Safadi, R; Thabut, D, 2021
)
0.93

Pharmacokinetics

ExcerptReferenceRelevance
" Plasma levels of ornithine and phenylacetic acid (PAA) and plasma/urinary levels of phenylacetylglutamine (PAGN) (primary metabolite of PAA) were regularly assessed; plasma ammonia level was the primary pharmacodynamic variable."( Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes.
Bajaj, JS; Bukofzer, S; Devarakonda, KR; Jamil, K; Potthoff, A; Pyrsopoulos, N; Rahimi, RS; Ram Bhamidimarri, K; Safadi, R; Thabut, D; Wang, L, 2022
)
0.99

Dosage Studied

ExcerptRelevanceReference
" Ammonia levels could shown to be reduced for up to 24 h in animal models until 120 h in patients with repeated dosing of the drug."( Ornithine phenylacetate revisited.
Jalan, R; Jover-Cobos, M; Noiret, L; Sharifi, Y, 2013
)
1.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's15 (68.18)24.3611
2020's7 (31.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.79 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index41.67 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (21.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (8.70%)5.53%
Reviews10 (43.48%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (47.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]